Absci Corp
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treat… Read more
Absci Corp (ABSI) - Net Assets
Latest net assets as of September 2025: $210.34 Million USD
Based on the latest financial reports, Absci Corp (ABSI) has net assets worth $210.34 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($244.99 Million) and total liabilities ($34.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $210.34 Million |
| % of Total Assets | 85.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | 167.34% |
| 10-Year Change | N/A |
| Growth Volatility | 202.29 |
Absci Corp - Net Assets Trend (2019–2024)
This chart illustrates how Absci Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Absci Corp (2019–2024)
The table below shows the annual net assets of Absci Corp from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $179.13 Million | +1.68% |
| 2023-12-31 | $176.18 Million | -35.80% |
| 2022-12-31 | $274.41 Million | -25.05% |
| 2021-12-31 | $366.11 Million | +446.39% |
| 2020-12-31 | $67.00 Million | +262.80% |
| 2019-12-31 | $-41.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Absci Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46822500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.01% |
| Other Comprehensive Income | $-4.00K | 0.00% |
| Other Components | $688.73 Million | 384.48% |
| Total Equity | $179.13 Million | 100.00% |
Absci Corp Competitors by Market Cap
The table below lists competitors of Absci Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SAMPYO Cement Co. Ltd
KQ:038500
|
$346.00 Million |
|
Maxvision Technology Corp
SHE:002990
|
$346.02 Million |
|
Nu Skin Enterprises Inc
NYSE:NUS
|
$346.07 Million |
|
CICOR TECHNOL.NAM. SF 10
F:CRLN
|
$346.09 Million |
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
$345.83 Million |
|
Beijing Kawin Technology Share-holding Co Ltd
SHG:688687
|
$345.83 Million |
|
Hotai Finance Corp
TW:6592
|
$345.78 Million |
|
Beijing Hanyi Innovation Technology Co. Ltd. A
SHE:301270
|
$345.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Absci Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 176,176,000 to 179,133,000, a change of 2,957,000 (1.7%).
- Net loss of 103,106,000 reduced equity.
- New share issuances of 86,557,000 increased equity.
- Other comprehensive income increased equity by 33,000.
- Other factors increased equity by 19,473,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-103.11 Million | -57.56% |
| Share Issuances | $86.56 Million | +48.32% |
| Other Comprehensive Income | $33.00K | +0.02% |
| Other Changes | $19.47 Million | +10.87% |
| Total Change | $- | 1.68% |
Book Value vs Market Value Analysis
This analysis compares Absci Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.86x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.45 | $3.03 | x |
| 2020-12-31 | $0.73 | $3.03 | x |
| 2021-12-31 | $3.95 | $3.03 | x |
| 2022-12-31 | $3.02 | $3.03 | x |
| 2023-12-31 | $1.91 | $3.03 | x |
| 2024-12-31 | $1.62 | $3.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Absci Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2274.06%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.19x
- Recent ROE (-57.56%) is below the historical average (-34.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -319.61% | 0.11x | 0.00x | $-2.47 Million |
| 2020 | -21.42% | -300.27% | 0.05x | 1.32x | $-21.05 Million |
| 2021 | -27.58% | -2111.25% | 0.01x | 1.16x | $-137.57 Million |
| 2022 | -38.23% | -1825.37% | 0.02x | 1.17x | $-132.35 Million |
| 2023 | -62.76% | -1933.65% | 0.03x | 1.23x | $-128.18 Million |
| 2024 | -57.56% | -2274.06% | 0.02x | 1.19x | $-121.02 Million |
Industry Comparison
This section compares Absci Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $46,072,599
- Average return on equity (ROE) among peers: -372.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Absci Corp (ABSI) | $210.34 Million | 0.00% | 0.16x | $345.85 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |